EUVIMEDEUVIMED entdecken
Crossref

COMPUTATIONAL REPURPOSING OF FDA-APPROVED DRUGS AS GPR119 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A HOMOLOGY MODELING AND MOLECULAR DOCKING APPROACH

Nema P, Kashaw SK

Bulletin of Pharmaceutical Research · 2025-08 · 15 (2)

DOI: 10.21276/bpr.2025.15.2.3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bulletin of Pharmaceutical Research, 2025-08. Verfasst von Nema P und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type-2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, beta-cell dysfunction, and hyperglycemia. G-protein-coupled receptor 119 (GPR119) is a promising therapeutic target, as its activation enhances insulin secretion and maintains glucose homeostasis with minimal adverse effects. Drug repurposing, leveraging FDA-approved drugs for new therapeutic indications, offers a cost-effective and time-efficient strategy to accelerate the drug discovery process. A 3D structure of the GPR119 receptor was developed using homology modeling and validated using Ramachandran plot analysis, ERRAT scores, and MolProbity metrics. FDA-approved drugs from the DrugBank database were prepared with the LigPrep tool, and the receptor's binding site was predicted using SiteMap. Molecular docking simulations were performed with the Glide module in Schrödinger, utilizing HTVS, SP, and XP protocols to assess binding interactions and rank potential agonists. The validated GPR119 model revealed a well-defined binding pocket conducive to ligand interactions. Docking studies identified Leuprolide (DB00007), Goserelin (DB00014), and Desmopressin (DB00035) as top-performing compounds, with docking scores of -11.132, -10.554, and -9.783 kcal/mol, respectively. These drugs demonstrated strong receptor-ligand interactions, including hydrogen bonding with critical residues indicative of their potential to activate GPR119. This study highlights the effectiveness of drug repurposing and computational techniques in identifying FDA-approved drugs with high potential as GPR119 agonists. The identified compounds, originally approved for conditions such as hormone regulation, represent promising candidates for further optimization and experimental validation in the treatment of T2DM. These findings underscore the potential of repurposing existing drugs to address unmet needs in diabetes management.

Zitieren

APA

P, N., & SK, K. (2025). COMPUTATIONAL REPURPOSING OF FDA-APPROVED DRUGS AS GPR119 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A HOMOLOGY MODELING AND MOLECULAR DOCKING APPROACH. Bulletin of Pharmaceutical Research, 15(2). https://doi.org/10.21276/bpr.2025.15.2.3

Vancouver

P N, SK K. COMPUTATIONAL REPURPOSING OF FDA-APPROVED DRUGS AS GPR119 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A HOMOLOGY MODELING AND MOLECULAR DOCKING APPROACH. Bulletin of Pharmaceutical Research. 2025;15(2). doi:10.21276/bpr.2025.15.2.3

BibTeX
@article{P2025,
  author = {P, Nema and SK, Kashaw},
  title = {COMPUTATIONAL REPURPOSING OF FDA-APPROVED DRUGS AS GPR119 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A HOMOLOGY MODELING AND MOLECULAR DOCKING APPROACH},
  journal = {Bulletin of Pharmaceutical Research},
  year = {2025},
  volume = {15},
  number = {2},
  doi = {10.21276/bpr.2025.15.2.3}
}
Kostenlos starten →